Non-Insulin Dependent Diabetes Mellitus (NIDDM) and Angiotensin Converting Enzyme 2 (ACE2): Diabetic Patients Treated With Antihypertensive Drugs

• Status: Unknown status
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

This feasibility study is designed to examine modulation of the relative activities of ACE and ACE2 in diabetic patients following treatment with the angiotensin type 1 receptor (AT1R) antagonist, Candesartan.

This study will provide a closer insight to the possible involvement of the renin-angiotensin system (RAS)-related enzymatic components in development or attenuation of vascular pathogenesis.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Rambam Health Care Campus
• Treatments: Antihypertensive Agents; Candesartan

Criteria

Inclusion Criteria:

• Signed informed consent

• Non-smokers

• Type II DM diagnosed patients

• Blood pressure < 135/90

• Serum HbA1C > 7%

• Serum creatinine < 1mg%

• Urine microalbumin < 300 mg/day

• Body mass index (BMI) < 35 kg/m2

Exclusion Criteria:

• Insulin-dependent diabetic patients

• Patient with persistent microalbuminuria

• Patient with history of severe hypertension

• Congestive heart failure

• Patient receiving renin-angiotensin-aldosterone system (RAAS)-related anti-hypertensive medications.

• Patient with major hepatic disease